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Abstract
Background: About 30% of stroke patients suffer from aphasia. As aphasia strongly affects daily life, most patients
request a prediction of outcome of their language function. Prognostic models provide predictions of outcome, but
external validation is essential before models can be used in clinical practice. We aim to externally validate the
prognostic model from the Sequential Prognostic Evaluation of Aphasia after stroKe (SPEAK-model) for predicting
the long-term outcome of aphasia caused by stroke.
Methods: We used data from the Rotterdam Aphasia Therapy Study – 3 (RATS-3), a multicenter RCT with inclusion
criteria similar to SPEAK, an observational prospective study. Baseline assessment in SPEAK was four days after stroke
and in RATS-3 eight days. Outcome of the SPEAK-model was the Aphasia Severity Rating Scale (ASRS) at 1 year,
dichotomized into good (ASRS-score of 4 or 5) and poor outcome (ASRS-score < 4). In RATS-3, ASRS-scores at one
year were not available, but we could use six month ASRS-scores as outcome. Model performance was assessed
with calibration and discrimination.
Results: We included 131 stroke patients with first-ever aphasia. At six months, 86 of 124 (68%) had a good
outcome, whereas the model predicted 88%. Discrimination of the model was good with an area under the
receiver operation characteristic curve of 0.87 (95%CI: 0.81–0.94), but calibration was unsatisfactory. The model
overestimated the probability of good outcome (calibration-in-the-large α = − 1.98) and the effect of the predictors
was weaker in the validation data than in the derivation data (calibration slope β = 0.88). We therefore recalibrated
the model to predict good outcome at six months.
Conclusion: The original model, renamed SPEAK-12, has good discriminative properties, but needs further external
validation. After additional external validation, the updated SPEAK-model, SPEAK-6, may be used in daily practice to
discriminate between patients with good and patients with poor outcome of aphasia at six months after stroke.
Trial registration: RATS-3 was registered on January 13th 2012 in the Netherlands Trial Register: NTR3271. SPEAK
was not listed in a trial registry.
Keywords: Aphasia, Stroke, Prognostic model, Validation, Outcome
* Correspondence: f.nouwens@erasmusmc.nl
1Department of Neurology, Erasmus MC University Medical Center, room
Nb-324, PO Box 2040, 3000, CA, Rotterdam, the Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Nouwens et al. BMC Neurology  (2018) 18:170 
https://doi.org/10.1186/s12883-018-1174-5
Background
Aphasia occurs in approximately 30% of stroke patients and
has a strong impact on everyday communication and daily
functioning [1, 2]. Shortly after stroke, patients and their
family are faced with major uncertainties regarding recovery
of communication. Consequently, there is a need for indi-
vidual estimation of the expected outcome. Adequate
personal prognosis may also contribute to optimizing indi-
vidual care, which is important as medical and paramedical
care becomes increasingly personalized [3]. Furthermore,
predictions of outcome may corroborate rationing of care,
in order to better distribute limited resources. Prediction of
post-stroke aphasia outcome is often based on models that
consist of determinants identified in a single dataset, e.g.
age, sex, aphasia severity and subtype; site, size and type of
the lesion; vascular risk factors and stroke severity [4–11].
Before a model can be used in daily practice, it should be
externally validated [3, 12]. This means that the
generalizability of a model is assessed in different cohorts
with more recent recruitment (temporal validation), from
other institutions (geographical validation), and by different
researchers [3]. To our knowledge, none of the few available
prognostic models predicting language outcome has been
externally validated [13–16].
Previously, our group has constructed a prognostic
model for the outcome of aphasia due to stroke. The
model was derived from the dataset of the Sequential
Prognostic Evaluation of Aphasia after stroKe (SPEAK)
study, and performed well [13]. The aim of the current
study was to externally validate the SPEAK-model in an
independent, yet comparable cohort of stroke patients
with aphasia.
Methods
The SPEAK-model
SPEAK was an observational prospective study in 147 pa-
tients with aphasia due to stroke conducted between 2007
and 2009 in the Netherlands [13]. Demographic,
stroke-related and linguistic characteristics of 130 partici-
pants, collected within six days of stroke, were used to
construct a model predicting good aphasia outcome one
year after stroke, defined by a score of 4 or 5 on the Apha-
sia Severity Rating Scale (ASRS) from the Boston Diagnos-
tic Aphasia Examination [17]. This scale is used for rating
communicative ability in spontaneous speech. The
ScreeLing, an aphasia screening test designed to assess the
core linguistic components semantics, phonology and syn-
tax in the acute phase after onset, was also included in the
model [18–20]. For detailed methods, results and discus-
sion we refer to the original paper [13]. The final
SPEAK-model contained six baseline variables: ScreeLing
Phonology score, Barthel Index score, age, level of educa-
tion (high/low), infarction with a cardio-embolic source
(yes/no) and intracerebral hemorrhage (yes/no) (Online
Additional file 1, Box A1). This model explained 55.7% of
the variance in the dataset. Internal validity of the model
was good, with an AUC (Area Under the Curve, where
the curve is the Receiver Operation Characteristic (ROC)
curve) of 0.89 [13].
Validation
For external validation of the SPEAK-model we used data
from the Rotterdam Aphasia Therapy Study (RATS) – 3, a
randomized controlled trial (RCT) studying the efficacy of
early initiated intensive cognitive-linguistic treatment for
aphasia due to stroke, conducted between 2012 and 2014
[21, 22]. RATS-3 was approved by an independent med-
ical ethical review board. Details about the study design,
methods and results have been reported elsewhere and a
summary will be provided below [21, 22].
Participants and recruitment
A total of 23 hospitals and 66 neurorehabilitation institu-
tions across the Netherlands participated in RATS-3. The
majority of participating institutions and local investigators
(90%) differed from those involved in SPEAK. In- and ex-
clusion criteria for both studies are presented in Table 1.
Prognostic variables
Patients with aphasia due to stroke were included in
RATS-3 within 2 weeks of stroke. At inclusion, the follow-
ing baseline variables were recorded: age, sex, education
level, stroke type (cerebral infarction or intracerebral
hemorrhage), ischemic stroke subtype (with or without a
cardio-embolic source). Level of independence was esti-
mated with the Barthel Index, a questionnaire containing
ten items about activities of daily life [23]. All participants
were tested with the ScreeLing to detect potential deficits
in the basic linguistic components [19, 24]. Spontaneous
speech samples were collected with semi-standardized in-
terviews according to the Aachen Aphasia Test-manual
[25]. Aphasia severity was assessed by scoring the spon-
taneous speech samples with the ASRS.
Outcome
In SPEAK, ASRS-scores were used to assess aphasia
outcome [17]. This six point scale is used to rate
spontaneous speech and ranges from 0: “No usable
speech or auditory comprehension” to 5: “Minimal
discernible speech handicaps; the patient may have
subjective difficulties which are not apparent to the
listener”. The SPEAK-model predicts the occurrence
of ‘good outcome’, i.e. an ASRS-score of 4 or 5 after
1 year. In RATS-3 follow-up was at 4 weeks, 3 and 6
months after randomization. ASRS-scores from the
RATS-3 cohort at 6 months after randomization were
used as outcome in the analysis, as this was closest in
time to the original model.
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Statistical analyses
Outcome in the RATS-3 cohort was divided in good
(ASRS-score of 4 or 5) or poor (ASRS-score < 4). To val-
idate the SPEAK-model we assessed discrimination and
calibration [3, 12, 26–28]. For both analyses predicted
probability of a good outcome was calculated using the
SPEAK-model (Online Additional file 1, Box A1).
Discriminative properties of the model were summa-
rized with the c index, similar to the AUC. Good dis-
crimination means that the model is able to reliably
distinguish patients with good aphasia outcome from
those with poor outcome.
We assessed the calibration properties of the model by
studying to what extent the predicted probability of aphasia
outcome corresponded with the observed outcome. A cali-
bration plot was constructed by ordering the predicted
probabilities of good aphasia outcome ascendingly and
forming five equally large groups. Per group, the mean prob-
ability of a good outcome at 6 months was calculated, result-
ing in five predicted risk-groups. Subsequently, in each
risk-group, proportions were calculated of participants with
an observed good outcome. These proportions were plotted
against the mean probability of a good outcome predicted
by the SPEAK-model. Outcomes of the linear predictor y,
calculated with the SPEAK-model, were used to fit a logistic
regression model predicting the dichotomous outcome of
good versus poor outcome to assess calibration-in-the-large
and the calibration slope. If calibration of a model is optimal,
the calibration-in-the-large α equals 0 and the calibration
slope β equals 1. In case of insufficient calibration we will re-
calibrate the prognostic model by adjusting the intercept.
Handling of missing data
For participants with missing outcome scores at 6
months, scores at 3 months after randomization were
used. If no scores were available at 3 months, patients
were excluded. Missing data for the other variables were
imputed using simple imputation: for binary and cat-
egorical variables the mode was imputed and means
were used for continuous variables.
Results
No outcome data at 6 months were available in 28 of
153 participants, and one participant was excluded be-
cause aphasia was later found to be caused by a brain
tumor. Reasons for missing outcome data were death (n
= 7), serious illness (n = 4), refusal (n = 16) and emigra-
tion abroad (n = 1). Of these 28 patients, 21 participants
were excluded because outcome at 3 months was also
not available. For 7 participants we used ASRS-scores at
3 months to impute missing values at 6 months. Baseline
data of patients in the validation sample (n = 131), as
Table 1 In- and exclusion criteria for participants in RATS-3 and in the SPEAK cohort
RATS-3 SPEAK
Inclusion: First-ever aphasia due to stroke First-ever aphasia due to stroke
Aphasia ascertained by a speech and
language therapist using the 36-item
Token Testa and/or a score < 5 on the
ASRS
Aphasia ascertained by a neurologist
and a speech and language therapist
Testable with the ScreeLing A score below the cut-off point of the
Token Test and/or the ScreeLing
Within two weeks of stroke onset Within two to six days of stroke onset
Age between 18 and 85 Adult
Language near-native Dutch Language near-native Dutch
A life expectancy of >six months
Able to tolerate intensive treatment
Exclusion: A subarachnoid or subdural hemorrhage
Success or feasibility of intensive language
treatment was severely threatened by:
Presence of one of the following criteria:
- severe dysarthria - severe dysarthria
- premorbid dementia - pre-stroke dementia (suspected or
confirmed)
- illiteracy - illiteracy
- severe developmental dyslexia - developmental dyslexia
- severe visual perceptual disorders - severe perceptual disorders of vision or
hearing
- recent psychiatric history - psychiatric history
aDe Renzi, E, Faglioni, P. Normative data and screening power of a shortened version of the Token Test. Cortex 1978;14:41–49
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well as those from the SPEAK cohort (n = 147) are pro-
vided in Table 2. Groups differed slightly with respect to
the baseline variables sex, level of education, type of
stroke and aphasia severity.
In the derivation SPEAK cohort (n = 130), 11% of the
patients had an ASRS-score of 4 or 5 at baseline (4 days
after stroke) and 78% had a good outcome after 1 year. In
the RATS-3 cohort we found a proportion of 21% with a
score of 4 or 5 at baseline (8 days after inclusion) and 68%
at 6 months. This is comparable to the 74% in SPEAK at
six months. The course of ASRS-scores in the RATS-3
and SPEAK cohort over time is presented in Fig. 1.
Discrimination of the SPEAK-model was good, with an
AUC of 0.87 (95% confidence interval: 0.81 to 0.94). In
Fig. 2a, the grey line depicts calibration of a hypothetically
perfect model and the 5 dots represent calibration values
in the five subgroups of patients, ordered by increasing
predicted probabilities and plotted against the actual pro-
portions of good outcome. The mean predicted probabil-
ity of good aphasia outcome at 1 year was 88%, while the
observed percentage was 68%, but this was measured at 6
months. The SPEAK-model was too optimistic in predict-
ing good aphasia outcome, with calibration-in-the-large of
α = − 1.98. The calibration slope of β = 0.88 indicated that
the predictor effects were slightly weaker in the validation
data than in the derivation data.
As Fig. 1 shows that there is still improvement after 6
months, we assume that the poor calibration-in-the-large
is at least partly due to the different timing of the outcome
measurement; 6 months versus 1 year. Thus, we updated
the SPEAK-model to predict outcome at 6 months instead
of 1 year by adapting the intercept (Online Additional file
1, Box A2). After revising the SPEAK-model, the calibra-
tion slope remained β = 0.88, but calibration-in-the-large
improved considerably: α = − 0.24 (Fig. 2b). We suggest re-
naming the original SPEAK-model predicting outcome at
1 year after stroke into SPEAK-12 and naming the up-
dated model SPEAK-6.
Discussion
We aimed to externally validate the published
SPEAK-model for the long-term prognosis of aphasia due
Table 2 Baseline model parameters of participants in the original SPEAK cohort and in RATS-3
SPEAK cohort (n= 147)
Derivation cohort
RATS-3 cohort (n= 131)
Validation cohort
Age, mean (SD), in years 67 (15) 65 (12)
Sex, n (%female) 78 (53%) 56 (43%)
Level of education, n (%)
High ■ 55 (42%) 60 (46%)
Low▲ 74 (57%) 71 (54%)
Unknown ♦ 2 (2%) 0
Type of stroke, n (%)
Non-cardio-embolic infarction 84 (57%) 81 (62%)
Cardio-embolic infarction 42 (29%) 23 (18%)
Intracerebral hemorrhage 21 (14%) 24 (18%)
Unknown ♦ 0 3 (2%)
Time since onset to inclusion, mean (range), in days 4 (2–6) 8 (1–18)
Barthel Index, median (IQR) ♦ 15 (7.75–20) 16 (6–20)
ScreeLing Phonology score, mean (SD)○ 14 (6) 15 (6.5)
ASRS-scores at baseline, n (%)
Score 0 18 (12%) 17 (13%)
Score 1 28 (19%) 21 (16%)
Score 2 33 (22%) 28 (21%)
Score 3 26 (18%) 38 (29%)
Score 4 27 (18%) 27 (21%)
Score 5 3 (2%) 0
Missing 12 (8%) 0
■ High = senior vocational education, higher education or university
▲ Low = no/unfinished elementary school, elementary school, unfinished junior secondary vocational education or junior secondary vocational education
♦ Imputed scores used for analysis: level of education = low; type of stroke = non-cardio-embolic infarction; Barthel Index score = 13 (n = 14)
○ ScreeLing Phonology scores range from 0 to 24
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to stroke using data from an independent cohort of stroke
patients with aphasia, RATS-3. The SPEAK-model per-
formed very well in terms of discriminating between good
(ASRS 4 or 5) and poor (ASRS < 4) outcome. However, cali-
bration was suboptimal, as it was overoptimistic in predict-
ing good aphasia outcome, partly due to the difference in
timing of the outcome which was 1 year in SPEAK and 6
months in RATS-3. Therefore, we proposed an updated
version of the SPEAK-model for the prediction of outcome
at 6 months.
Prognostic models are used in clinical practice to predict
possible outcomes or risks of acquiring certain diseases. To
our knowledge, apart from the SPEAK-model, only three
other models to predict outcome of aphasia after stroke
have been published [14–16]. One logistic regression model
predicting early clinical improvement in stroke patients
with aphasia was constructed based on findings from
CT-angiography and CT-perfusion [15]. Clinical applicabil-
ity of this model is limited, as these detailed CT-data are
rarely available in daily practice. Another logistic regression
model addressed the effect of speech and language treat-
ment (SLT) on communication outcomes [14]. The authors
found that the amount of SLT, added to baseline aphasia se-
verity and baseline stroke disability significantly affected
communication 4 to 5 weeks after stroke. Baseline variables
were recorded within 2 weeks of stroke. Recently, a model
was published predicting everyday communication ability
(Amsterdam-Nijmegen Everyday Language Test; ANELT)
at discharge from inpatient rehabilitation based on ScreeL-
ing Phonology and ANELT-scores at rehabilitation admis-
sion [16]. These models predict outcome of aphasia
recovery only in patients treated with SLT, but do not pre-
dict outcome before treatment is initiated. Furthermore, in
both studies the cohort included only patients eligible for
intensive treatment.
For a prognostic model to be valid and reliable, it is im-
portant to evaluate the clinical applicability and
generalizability of the model [29]. Inclusion criteria in
SPEAK and RATS-3 were not strict, so that both cohorts
can be considered representative of acute stroke patients
with aphasia in general. The SPEAK-model is valuable for
predicting aphasia outcome early after stroke in clinical
practice as it includes easily available baseline variables
[13]. It requires only the Barthel Index score and the
ScreeLing Phonology score to be collected outside clinical
routine. The Barthel Index is commonly assessed in the
acute phase, allowing for application of this model without
much effort [30].
Our study is the first to validate a model for the prognosis
of aphasia outcome in an independent cohort. Determining
Fig. 1 ASRS-scores over time in SPEAK and RATS-3. ASRS-scores: 5 = minimal discernible speech handicap, some subjective difficulties that are
not obvious to the listener; 4 = some obvious loss of fluency in speech or facility of comprehension, without significant limitation in ideas
expressed or form of expression; 3 = able to discuss almost all everyday problems with little or no assistance, reduction of speech and/or
comprehension; 2 = conversation about familiar topics is possible with help from the listener, there are frequent failures to convey an idea; 1 =
all communication is through fragmentary expression, great need for inference, questioning and guessing by listener, limited information may be
conveyed; 0 = no usable speech or auditory comprehension
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whether a model generalizes well to patients other than
those in the derivation cohort, is crucial for the application
of that model in daily practice [12, 26, 27, 29]. We found
that the SPEAK-model is able to adequately distinguish
stroke patients with aphasia who will recover well with re-
spect to functional verbal communication from patients who
will not. The model appears less accurate when it comes to
the comparison of predicted and actual good outcome.
A first possible explanation may be the different inter-
vention in the two studies. In SPEAK, patients received
usual care and researchers did not interfere with the treat-
ment provided. In RATS-3, treatment was strictly regu-
lated, as in this RCT patients were randomly allocated to
4 weeks of either intensive cognitive-linguistic treatment
or no treatment, starting within 2 weeks after stroke. After
this period both groups received usual care, as in SPEAK.
In RATS-3 we found no effect of this early intervention
and both intervention groups scored equally on all
outcomes. Thus, we believe treatment does not explain
the poor calibration.
Second, there was a difference between SPEAK and
RATS-3 with respect to the interval between stroke onset
and inclusion of patients. In SPEAK, patients were in-
cluded on average 4 days after onset and in RATS-3 after
8 days. This seemingly small difference might in fact have
caused substantial differences in the prognostic effect of
the baseline ScreeLing and Barthel Index scores. Recovery
can occur rapidly early after stroke, as was shown in the
SPEAK cohort, with a statistically significant improvement
on the ScreeLing Phonology score between the first and
second week after stroke [31]. Hence, these predictors
might have different effects in the RATS-3 cohort, as rep-
resented in the suboptimal calibration slope.
Third and most importantly, calibration is likely to
have been influenced by a different follow up dur-
ation, which was 6 months in RATS-3 versus 1 year
a
b
Fig. 2 Calibration plots of the SPEAK-model and updated SPEAK-model. a Calibration plot of the original SPEAK-model, SPEAK-12. b Calibration
plot of the updated SPEAK-model, SPEAK-6
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in SPEAK. In SPEAK, ASRS-scores improved signifi-
cantly up to 6 months after aphasia onset, but no sig-
nificant improvement was found between 6 and 12
months [31]. We used this finding for the design of
the present study to justify the earlier time-point for
the outcome in RATS-3. Although in SPEAK no sta-
tistically significant improvement in ASRS-scores was
found between 6 and 12 months after stroke, some
improvement still occurred [31]. Of the participants
from SPEAK 74% had an ASRS-score of 4 or 5 at 6
months after stroke, which is fairly similar in RATS-3
at that time-point (68%). It is likely that calibration
would have been better if the outcome was deter-
mined at 12 months in the RATS-3 cohort, because
of the small, but apparent recovery between 6 and 12
months after stroke.
We therefore suggest an updated version, SPEAK-6, to
predict outcome at 6 months. More extensive updating
could imply refitting the models to the new dataset, to
obtain new model coefficients [32–34]. However, as the
model discrimination was good, we updated only the
intercept to make the model applicable to predict out-
come at 6 months, when the average probability of a
good outcome is lower than at 1 year. We recommend
that the updated SPEAK-6 is validated in the future in
new independent datasets.
This study shows again that the external validity of
prognostic models in new settings should always be
carefully assessed. However, it should also be noticed
that perfect calibration might in fact be impossible, as it
implies that a model perfectly predicts outcome for all
patients [35].
Strengths and limitations
The major limitation of this validation study is the differ-
ence in time post onset at which predictor and outcome
data were collected. Strength is that the RATS-3 and
SPEAK cohorts are comparable, due to similar inclusion
criteria. However, whereas participation in SPEAK merely
involved periodic language evaluations, RATS-3 was an
intervention trial, with either early intensive treatment or
no early treatment. Due to these experimental interven-
tions many patients refused participation. Also, selection
criteria for RATS-3 were slightly stricter than in SPEAK
regarding the potential to receive early intensive treat-
ment. Consequently, the SPEAK and RATS-3 cohorts
might represent slightly different populations of stroke pa-
tients with aphasia, albeit closely related [26]. Therefore,
as in all clinical trials, one must be careful in generalizing
the results to all stroke patients with aphasia [36].
Although both the derivation cohort and the validation
cohort consist of well over a hundred participants,
sample sizes may be considered rather small for ad-
equate modelling [28, 36]. This is reflected in the slight
imbalance of baseline characteristics between both study
cohorts. This imbalance may underpin the necessity of
larger sample sizes to better reflect the population of
stroke patients with aphasia. Furthermore, in both co-
horts a fairly large proportion of patients with mild
aphasia (baseline ASRS > 3) was included. Although this
was a reflection of the population, it may have influ-
enced the model, as patients with mild aphasia are
known to often fully recover [6, 37].
A much debated issue is the potential lack of sensitiv-
ity of rating scales for analyses of spontaneous speech in
aphasia [38]. In the current study, we dichotomized out-
come, further reducing sensitivity. It can be argued that
the definition of “good outcome” with an ASRS of 4 or 5
is somewhat optimistic. A score of 4, or sometimes even
5, does not imply full recovery. Patients with a score of 4
still experience difficulties with word finding or formu-
lating thoughts into language.
The ScreeLing is currently only available in Dutch,
which severely limits the applicability of the predic-
tion model. However, adaptation to other languages
should not be very complicated as the ScreeLing
Phonology subscale contains well-known tasks to
measure phonological processing, e.g. repetition, dis-
crimination of minimal pairs, and phoneme/grapheme
conversion [20]. Including linguistic functioning, as a
possible predictor in prognostic models seems essen-
tial, as linguistic functioning, in particular phonology,
appears to be a better predictor than overall aphasia
severity [13, 16, 39]. At the moment the ScreeLing is
being translated into English, German and Spanish,
and more languages are to come.
The Barthel Index was included in the original model
as a measure of overall stroke severity. Although its reli-
ability is good, it may be debated whether the Barthel
Index score accurately reflects stroke severity, as the
score is influenced by factors related to health care man-
agement choices, such as receiving a urinary catheter or
feeding tube on intensive care units. Despite its short-
comings the Barthel Index was found to be a valid out-
come measure for stroke trials [40].
Finally, the RATS-3 database contained several
missing values. Of the participants who refused evalu-
ation at 6 months, three had fully recovered, which
may have introduced a slight bias. Missing values for
other variables in the model mostly resulted from in-
consistencies in reporting the scores. We used gener-
ally accepted methods for imputation of the data and
for most variables few data were missing (< 5%) [27].
For the Barthel Index 10% had to be imputed, which
is a fairly large proportion. There were no clear rea-
sons for these missing values, other than clinicians
sometimes just forgot to fill out the score form,
which in our view justifies imputation.
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Conclusion
The original SPEAK-model, renamed SPEAK-12, performs
well in predicting language outcome after 1 year in patients
with aphasia due to stroke. As calibration was initially un-
satisfactory, we propose an updated version of SPEAK-12
for the prediction of the probability of good language out-
come at 6 months: SPEAK-6. Further external validation of
SPEAK-12 and SPEAK-6 is recommended. Special atten-
tion should be given to timing, as time after stroke onset at
which predictors and outcome data are collected appears
crucial for adequate model validation. Our results show
that SPEAK-6 may be used in daily practice to discriminate
between stroke patients with good and patients with poor
language outcome at 6 months after stroke.
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Afasietherapie Amsterdam, Rivas Gorinchem, Aafje Rotterdam, De Zellingen
Rijckehove Rotterdam, Saffier de Residentie Mechropa The Hague, Respect
Zorggroep Scheveningen The Hague, Revant Rehabilitation Breda, Surplus Zorg
Zevenbergen, Careyn Spijkenisse, De Vogellanden Zwolle, De Hoogstraat
Utrecht, Woonzorgconcern IJsselheem Zwolle, Osira Amsterdam, Stichting Sint
Jacob Jacobkliniek Haarlem, Viattence De Wendhorst Heerde, Zonnehuisgroep
IJssel-Vecht Zwolle, Zorgbalans Driehuis, Novicare Best, Libra Zorggroep
Blixembosch Eindhoven, Logopedie Zandvoort Zandvoort, Practice M.P. de Boer
Haarlem, Brabantzorg Ammerzoden, Zorggroep Elde Boxtel, Van Neynselgroep
Den Bosch, Vivent Rosmalen.
Participants and/or their proxies gave written informed consent to
participate in the original studies. All SL-therapists and research team
members that were involved in the informed consent procedure for these
studies were instructed to always include patients and their proxies in the
process. Consequently, candidates could discuss their participation with
someone they trusted and proxies of the candidate also approved
participation. The only exception was when candidates did not have a next
of kin. If baseline tests showed a severe aphasia, these patients were not
deemed eligible to provide informed consent solely.
In addition to information provided in one or more conversations,
candidates were provided with information leaflets containing all details of
the studies; one leaflet with all information for the proxies and one
simplified “aphasia friendly” version.The informed consent procedure and
materials used were approved by het Medical Ethical Committee of Erasmus
MC University Medical Center.
By consenting to participate in SPEAK and RATS-3 participants also approved
that their anonymized data could be used in post-hoc analyses. Hence,
additional consent for this study was not necessary.
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